U.S. Markets closed

Kymera Therapeutics, Inc. (KYMR)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
62.95-1.95 (-3.00%)
At close: 4:00PM EDT
Full screen
Loading interactive chart...
  • TheStreet.com

    AbCellera, Kymera and Diamondback Move in After-Hours

    Among stocks seeing big moves in after-hours trading Thursday, AbCellera Biologics gained after saying it won emergency use authorization from the Food and Drug Administration for a treatment of people who've been exposed to COVID. The company said its bamlanivimab drug can now be used in combination with another drug called etesevimab "to treat high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination." The move "provides a way to protect the significant number of people who, because of their situational exposure risk or medical condition, remain vulnerable to COVID-19," said Carl Hansen, CEO and president of AbCellera, in a statement.

  • GlobeNewswire

    Kymera Therapeutics to Present at Upcoming September Investor Conferences

    WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at two upcoming investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference: a fireside chat webcast will be available live on Thursday, September 9, 2021 at 1:15 p.m. ET.H.C. Wainwright 23rd Annual

  • Simply Wall St.

    Time To Worry? Analysts Are Downgrading Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Outlook

    Today is shaping up negative for Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) shareholders, with the analysts delivering a...